Table 1.
The top ten most cited publications in CDK4/6 inhibitor research
| Study title | First authors | Journal | Year | Total citations | Impact factor | Quartile in category |
|---|---|---|---|---|---|---|
| Cyclin-dependent kinase pathways as targets for cancer treatment | Shapiro, GI | J CLIN ONCOL | 2006 | 704 | 32.956 | Q1 |
| Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts | Fry, DW, Harvey, PJ | MOL CANCER THERAP | 2004 | 692 | 5.615 | Q1 |
| PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro | Finn, RS, Dering, J | BREAST CANCER RES | 2009 | 669 | 4.988 | Q2 |
| The history and future of targeting cyclin-dependent kinases in cancer therapy | Asghar, U | NATURE REVIEWS DRUG DIS | 2015 | 618 | 64.794 | Q1 |
| Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | Hortobagyi, G. N. | NEW ENGL J MED | 2016 | 549 | 74.699 | Q1 |
| Cyclin D-dependent kinases, INK4 inhibitors and cancer | Ortega, S | BBA-REV CANCER | 2002 | 537 | 7.365 | Q1 |
| Multiple viral strategies of HTLV-1 for dysregulation of cell growth control | Yoshida, M | ANN REV OF IMMUNOLY | 2001 | 348 | 19.9 | Q1 |
| AKT/PKB phosphorylation of p21(Cip/WAF1) enhances protein stability of p21(Cip/WAF1) and promotes cell survival | Li, Y | J BIOL CHEM | 340 | 4.238 | Q2 | |
| Cycling to cancer with cyclin D1 | Diehl, JA | CANCER BIOL THERAP | 2002 | 328 | 3.659 | Q2 |
| Targeting CDK4 and CDK6: From Discovery to Therapy | Sherr, CJ | CANCER DIS | 2016 | 311 | 29.497 | Q1 |